Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance
NCT02534727 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 215
Last updated 2022-03-29
Summary
Background:
Many people around the world get tuberculosis (TB) and non-tuberculous mycobacteria (NTM) infections. Sometimes medicine that treats these infections does not get to where the bacteria are in the lungs. Researchers want to find a way to tell if enough medicine is getting to where it is needed in the lungs. They will look at how much medicine is in your sputum (what you cough up) compared to how much is in your blood. They will also investigate a new test to quickly figure out what medicines are likely to treat TB effectively.
Objective:
To determine the relationship between the concentration of TB drugs in plasma and sputum over time.
Eligibility:
People ages 18 and older who have TB or NTM infection that is suspected to be drug resistant. They must be taking TB or NTM medicines.
Design:
Participants will be screened with medical history.
Participants will be in the study for 2 8 days.
Participants will give 3 or more sputum samples over at least 2 different days. They will cough sputum into a cup.
Participants will have blood drawn 4 times a day on 2 different days.
Conditions
- Tuberculosis
- Non-Tuberculosis Mycobacteria
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Clifton E Barry, Ph.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-01-27
- Primary Completion
- 2020-12-31
- Completion
- 2020-12-31
Countries
- United States
- China
Study Locations
More Related Trials
-
The Safety of Tuberculosis Treatments by Oral Inhalation
NCT01785927 ·Status: UNKNOWN ·Phase: PHASE1
-
Pharmacokinetic Evaluation and Local Tolerability of Dry Powder Amikacin Via the Cyclops™
NCT04249531 ·Status: UNKNOWN ·Phase: PHASE1
-
Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis
NCT02035488 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection
NCT03597347 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable Chronic Bronchitis
NCT00205647 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery
NCT07136987 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin
NCT00634192 ·Status: COMPLETED ·Phase: PHASE3
-
ATP Level and Cough Sensitivity to ATP in Subjects With Refractory/Unexplained Chronic Cough
NCT05265871 ·Status: COMPLETED
-
A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis
NCT00255983 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
NCT05675072 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
NCT05766267 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
NCT06603246 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly
NCT04139915 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection
NCT00794586 ·Status: COMPLETED ·Phase: PHASE2
-
Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria
NCT01315236 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes
NCT04409327 ·Status: TERMINATED ·Phase: PHASE2
-
The Safety, Feasibility, and Repeatability of Inhaled ATP Cough Challenges
NCT07085975 ·Status: RECRUITING ·Phase: PHASE1
-
Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)
NCT02968212 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome
NCT05279352 ·Status: UNKNOWN ·Phase: PHASE2
-
Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis.
NCT05258877 ·Status: COMPLETED
-
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
NCT05628740 ·Status: COMPLETED ·Phase: PHASE1
-
N-Acetylcysteine for Patients With COPD and ChronicBronchitis
NCT01599884 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung
NCT02113397 ·Status: TERMINATED
-
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease (COPD)
NCT00549445 ·Status: COMPLETED